Therapy-induced IGF1R signaling as an actionable vulnerability in oncolytic virotherapy
Molecular Therapy · 2026-10 · 34 (10) · 5646-5648
DOI: 10.1016/j.ymthe.2026.08.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-10. Verfasst von Alexandra A Miller und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; The University…. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NINDS NIH HHS, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School o…
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- Cancer Prevention and Research Institute of Texas
- National Institute of Neurological Disorders and Stroke
- National Institutes of Health
- American Legion
- National Institutes of Health National Cancer Institute
- American Cancer Society
Zitieren
APA
Miller, A. A., Lee, T. J., & Yoo, J. Y. (2026). Therapy-induced IGF1R signaling as an actionable vulnerability in oncolytic virotherapy. Molecular Therapy, 34(10), 5646-5648. https://doi.org/10.1016/j.ymthe.2026.08.032
Vancouver
Miller AA, Lee TJ, Yoo JY. Therapy-induced IGF1R signaling as an actionable vulnerability in oncolytic virotherapy. Molecular Therapy. 2026;34(10):5646-5648. doi:10.1016/j.ymthe.2026.08.032
BibTeX
@article{Miller2026,
author = {Miller, Alexandra A and Lee, Tae Jin and Yoo, Ji Young},
title = {Therapy-induced IGF1R signaling as an actionable vulnerability in oncolytic virotherapy},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {10},
pages = {5646--5648},
doi = {10.1016/j.ymthe.2026.08.032}
}
EUVIMED